Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (March 2013)
44 slides from Fluoropharma Medical's investor presentation, Mar 6, 2013
Slide 1: FluoroPharma: Cardiac PET
Fluorde a February 21, 2013 Cardiac PET CONFIDENTIAL | wm fluoropharma.com
Slide 2: History, background and focus
FluoroPharma Medical Inc. History, background and focus The company Three active cardiac Imaging programs for pet imaging Patient management a = Founded in 2003 in Boston with technology exclusively licensed from Massachusetts General Hospital ‘Molecular imaging focused on Cardiology Next generation
Slide 3: Development Portfolio
Fluorog FluoroPharma Medical Inc. Development Portfolio BFPET™ CardioPET™ VasoPET™ 12 million potential pati 7 For use in combi illion potential patients = 56 million potential patients Detects regions of fatty acid «+ —Avidly taken stress-testing in patients with uptake for metabolism inflammatory
Slide 4: Cardiovascular Disease
Fluorde — Cardiovascular Disease CONFIDENTIAL wm uoropharma.com
Slide 5: The Single Largest Cause of Global Mortality
“The Single Largest Cause of Global Mortality” 30% of all deaths due to CVD, at an estimated annual cost of $863B "nono otea cer cnW e 17227 9 seta oe Cost |_| Market Trends — Global Cardiovascular Disease 230% 729000 $280 ion _ we EU. 40% 2.000000 $262 bition co wep ig Aa 20% 7.900000 $120 bon Glob
Slide 6: Market Trends — Global Cardiovascular Disease
Market Trends — Global Cardiovascular disease Existing Population Trends & Key Growth Drivers ‘OverweightObese Uncontrolled Heart Failure + omeght —e Hype Hg oC rges, Living and Dead Percent ot Popustion pesged A 8 eB a Discharges in Towns of E8888 tor saree toast 8000 = = = a NODS, NHLBI COC andthe
Slide 7: Disease Progression Pathway
ease Progression Pathway Earlier detection and indentification of "at risk” patients reduce overall cost Medical Concems that Present Best High Blood Targets for Healthcare Cost Redu: Pressure Blood Chemistry 1 Coronary Artery Diabetes Obesity Disease (CAD) Heart disease Mental health Chronic lung d
Slide 8: Treatment Flow Model for BFPET and potentially CardioPET
Treatment Flow Model for BFPET and potentially CardioPET ‘Taee area varity of patsy by utmatty ecatvse teat, based on ne 2 wall ae ne retaraing Dhyelcan and redngptcan [| Coronary Artery Disease © wel: BEPET & CardioPET ® Myocardial Viability Testing: CardioPET ‘Souroe:_wuntes.or. Aoesseg November 2
Slide 9: Treatment Flow Model for CardioPET
Treatment Flow Model for CardioPET ‘The triage of patients with suspected acute coronary syndrome (ACS) in the emergency room isa time-consuming diagnostic challenge. | Acute Coronary Syndrome of noninvasve imagin res ime (208) ~ Mt os 04m
Slide 10: Evaluation: Function vs. Anatomical Cardiac Imaging Modalities for CAD
Evaluation: Function vs. Anatomical Cardiac Imaging Modalities for CAD Key Observations CJ Coronary Artery Disease PORTA TEES = Functional tests can provide more accurate Anatomical + MPLSPECT Giagnossforeary-stage patents ‘Tests = MPI-PET — Majority of symptoms are not due to “cr ——— changes in ana
Slide 11: Imaging Modalities for CAD: Advantages and Disadvantages
Flu010 Coronary Artery Disease Evaluation: Imaging Modalities for CAD—Advantages and Disadvantages There are multiple ad ana ages wath used . imaging modalties. J Focus =P J wosstty Tvantages | isadvantages a See er ae eee —— : + Widespread availabilty, Weight imi (400 to) + Large number of exper re
Slide 12: Evaluation: MPI procedures predominate
Coronary Artery Disease Evaluation: MPI procedures predominate total of approximately 11.3 millon MPI procedures (SPECT and PET) were performed in 2007. 1+ Twotypes of cardiac stress studies are commonly used to diagnose CAD patients ~ Nuclear stress testing. which evaluates myocardial perfusion Str
Slide 13: U.S. PET Scanner Placement (2009)
U.S. PET Scanner Placement (2009) 2000 systems: 61% Hospitals, 39% Non-Hospitals mas49 [os Total: Hospital:1 228 Non-Hosptas: 772 ‘Source, Burk Andreas etal Economic Evaation of PET and PETICT im Onesegy:Eviéence an Methaclogi APpCaces J Nac ed Technol Mach 20103867 Floto Parramatta wen uma ¢ Ps |
Slide 14: U.S. Cyclotron Distribution Network
U.S. Cyclotron Distribution Network ~100 FDG Production Sites (Cardinal Health, IBA, PETNET) © eatease (© canal inh Ceton erent (© Cyt Mangere emer Souce_ Company weottes, Inston Tia topes has 4 eyeltore in the Southeast Flues esrarma
Slide 15: Nuclear Cardiology
Fluorde — Nuclear Cardiology CONFIDENTIAL wm uoropharma.com
Slide 16: Clinical drivers, unmet needs and benefits of PET vs. SPECT in Cardiology
Clinical drivers, unmet needs and benefits of PET vs. SPECT in Cardiology Advancing the Transition to PET in Clinical Cardiology Drivers and Benefits: Ira Nala Cady [ Gary V. Haller, MD, PaD=Y iss 4. Continued advancements in scanner " , ” technology 2. Fusion of anatomical and functional studies Ex
Slide 17: Market Trends Molecular Imaging
Market Trends Molecular Imaging Key regional markets: nuclear medicine usage drivers by disease area "Cardiology “Oncology “Other = NonHospital “Hospital Cardiology = Oncology -—«*Non-Hostptal_ Hospital Thyrod—— ther 21.8M Procedures 14.8M Procedures, 83M Procedures _—_1.8M Procedures 100% , 100% ’
Slide 18: Technical Trends - Growth drivers enabling shift in technology
| | Technical Trends - Growth drivers enabling shift in technology Technical and Diagnostic Benefits of PET vs. SPECT a Image + Improved overallimage quality ‘Dynamic tomographic imaging + High Definition Hybrid imaging: calcium scoring, CT angiography + Improved spatial, temporal and contrast resol
Slide 19: Advantages and disadvantages of SPECT perfusion imaging
= Familiarity among providers = Standardized protocols = Familiarity among referring physicians (valuable indications) = Large evidence base for diagnostic accuracy, risk stratification, guiding patient management = Nuclear medicine cameras and SPECT imaging widely available = Newer hardware and/or
Slide 20: Global Market for PET/SPECT (2010-2020)
Global Market for PET/SPECT (2010-2020) PET new unit sales projected to exceed SPECT by 2017 10 8 ° Es TTT 2011 2012 2013 2014 2015 2016, 2010 2011 2012 2013 2014. 2015 2016, o 88888888 New Unit s: —peT —sPect ia 2011 2012 2013 2014 2015 2016 2017 2018 2018 2020 aeee88 8 Number of SPECT Cameras Swit
Slide 21: OEM Growth of US and worldwide
OEM Growth of US and worldwide Installed base of PET scanners from 2004-2017 Us PET Scanners installed ——-Worawide Scanners installed 2,000 4.500 ee ee ee eee eee eee PET vs. PETICT = Flsed PETICT ‘= Flved PET Only Souce_ Beech Systm ne. atetfor PET Rasepharmaceuteaisand PET imap Not 2010 Fluor aram
Slide 22: Market Drivers for New PET Products
Market Drivers for New PET Products Utilization is increasing in fixed PET installations ‘Comprehensive adoption of Growth in PET procedural Low, but increasing early diagnosis will improve volumes capacity utilization Cr relegate CAGR + At capacity, more patients could 2000 “65% | _ 4) Under Uitliz
Slide 23: PET Growth Expectations
PET Growth Expectations Predicted to grow to 1/3 of U.S. nuclear cardiology procedures ‘Approximate Use of Cardiac Diagnostic Testing {Future of Nuclear Cardiology in 2020 100% 90% 20% 70% SPECT & om SPECTICT 50% 40% 20% 20% 10% % = ° ° g Zz \ PET & PET/CT a7 8 3 g 6 | g 8 g \ BS fF 2 \ 8 s i \ ‘ada
Slide 24: ASNC 2010 Information Statement
ASNC 2010 Information Statement Recommendations for reducing radiation exposure in myocardial perfusion imaging include adoption of PET Patient referred for MPI Is a comparable Is study agnostic test IsPET Appropriate? Ye without radiation Ne available? Yes Consider PET °S available? ° {No {yes To C
Slide 25: Improved Patient Management - SPECT vs. PET
Improved Patient Management - SPECT vs. PET PET enables less downstream catheterizations & revascularizations Percent =SPECT © PET 35 30 25 20 15 : a 5 o8 Catherization Revascularization Parramatta wen uaa in ¢
Slide 26: Cardiac PET (Rb-82) vs. SPECT Perfusion Imaging
Cardiac PET (Rb-82) vs. SPECT Perfusion Imaging Comparisons of PET and SPECT available today "Tc-MIBI SPECT "Rb PET Comparison of SPECT and PET Perfusion Imaging Panel A illustrates improved specificity with PET. A fixed defect in the inferior wall on SPECT is absent on PET, suggesting the presence
Slide 27: Cardiac PET (F-18) vs. SPECT (MIBI) Rest/Stress Perfusion Images
Cardiac PET (F-18) vs. SPECT (MIBI) Rest/Stress Perfusion Images BFPET images have higher resolution than sestamibi on a qualitative basis -_~ Stress = MIBI Rest Stress fy) fy) BFPET Rest fy fy ¢ Fluoro, Ferma ta
Slide 28: Published literature on Cardiac PET
Published literature on Cardiac PET Quantitatively PET has high sensitivity and specificity across many studies a °NH3- ®RbINHS Rb = NCu-PTSM *0.H,0 Schelbert et al Tamaki et al Yonekura et al Tamaki et al Laubenbacher et al Hussmann et al Gould et al Demer et al Goetal Stewart et al Marwick et al G
Slide 29: SPECT vs. PET Perfusion
Spatial resolution Stress Protocol Procedure Ventricular function Attenuation correction Energy Radiation Images Hybrid with CT Availability SPECT vs. PET Perfusion PET provides significant clinical and workflow advantages relative to SPECT 12-15mm Exercise, pharmacologic 1 or 2 days 2-4 hours Post-
Slide 30: Cardiac SPECT, PET and CT Radiation Exposure
Cardiac SPECT, PET and CT Radiation Exposure PET allows for lower radiation exposure Imaging Modality & Tracer ‘SPECT: Dual isotope imaging Radiation Dosimetry SNC recommends reduction of SPECT Thallium stress-rest ‘SPECT: Rest-stress single isotope * TTechnetium SPECT. Stress-only Technetium ‘SPECT
Slide 31: Why PET now?
Why PET now? Distribution infrastructure and increased install base will enable transition SEES) - PET has a significantly higher rate of specificity and sensitivity than SPECT to better + Leads to decreased attenuation artifacts and fewer inconclusive studies medicine + Provides a more accurate dia
Slide 32: Reimbursement - Coronary Artery Disease
Reimbursement - Coronary Artery Disease CMS Coding for key cardiac procedures (PET) -*-Stress Test “=-SPECT MPI SPECT Myocardial “®=PET MPI 1600 5 1400.95 1429.36. @ 1400 z 1107.36 5 1200 | 1038.06 1056.12 z wn | 24 754.85 774.13 775.09 759.9 @ 800 _ 672.48 gg 43, 600 — 399.62 400 5 253,65 309.68 31
Slide 33: FPMI Portfolio Review
Fluorde — FPMI Portfolio Review CONFIDENTIAL wm uoropharma.com
Slide 34: Making the Invisible, Visible
| | Making the Invisible, Visible For measuring cardiovascular For detecting regions of fatty For detecting inflamed plaques flow take blood acid uptake * For use in combination with * Modified fatty acid (MFA) * Avidly taken up by stress-testing in patients with designed to optimize inflammatory ce
Slide 35: BFPET Clinical Use
| BFPET Clinical Use MYOCARDIAL PERFUSION IMAGING CURRENT DIAGNOSTIC TEST CLINICAL NEED Fluareg, arma Evaluate patients with known or suspected CAD Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress Perfusion imaging with SPECT tracers (e.g. MIBI, tetrophosmin, T-201
Slide 36: BFPET Phase I Trial Findings
| | BFPET Phase | Trial Findings Results show excellent perfusion imaging BFPET Phase la completed properties * 12 healthy volunteers ages 20-85 * Rapid extraction from blood + No adverse events * Stable heart uptake over time * No clinically significant changes noted in * High target to background
Slide 37: The BFPET Opportunity
| The BFPET Opportunity Est. 5 Year Revenue $691 million Est. PET Market Market Patients Size Myocardial 12 million 3.6 million perfusion imaging N Lah) | k “Pharma Projected BFPET Scans Millions Year 1 Year 3 Year 5
Slide 38: Market Trends & Growth — current and potential
Market Trends & Growth — current and potential BFPET™, CardioPET™ & VasoPET™ address existing & untapped markets Established products New products Tesom MM RoPeT MM erret MM cardioPeT [ll vasoPeT ‘12 mlion seans per year (8+4) yn scans per year (12+6+0.9) Unmet market pp. 6M / yr Exercise 7 j ‘tess
Slide 39: CardioPET Clinical Use
| CardioPET Clinical Use Identify patients that may benefit from PCI or revascularization and C87 guide intervention ASSESSMENT Evaluate CAD in patients that cannot exercise = Invasive coronary angiography CURRENT TREATMENT 1.3 million diagnostic angiography procedure at $26,000 and 1.3 million PCI
Slide 40: CardioPET Phase I Results
CardioPET Phase | Results Normal i OH Subject CAD Subject Fatty acid analog that detects regions of metabolic insufficiency * CardioPET promising safety with no AEs detected = Clinical findings consistent with MPI SPECT * Quality of CardioPET images substantially superior to MPI SPECT 15 minute scan
Slide 41: The CardioPET Opportunity
| The CardioPET Opportunity Est. 5 Year Revenue Millions ‘$605 million 2.0 Est. Est. PET FP 1.6 Market Patients Market Size Share CAD 3.8 million 41 million 32% | 1.2 diagnosis at rest Cardiac 1.6 million 0.5 million 80% Viability assessment o4 Myocardial 12 million 3.6 millon 7.2% perfusion 0.0 ima
Slide 42: VasoPET Indications and Clinical Use
[| VasoPET Indications and Clinical Use EVALUATION OF CURRENT DIAGNOSTIC PRACTICE CLINICAL NEED Patients with acute cardiac event or stroke (risk of recurring event) Therapy following acute cardiac event or stroke (e.g., Plavix, lipid therapy, new treatments) Clinical symptoms; several imaging agent
Slide 43: VasoPET: Detection Of Inflamed Atherosclerotic Plaque
| | VasoPET: Detection Of Inflamed Atherosclerotic Plaque WHY INFLAMMATION IMAGING? * Diagnosis before symptoms occur $ * Crucial role at all stages of atherosclerosis « May aid drug development DEVELOPMENT STATUS * Preclinical testing completed + IND preparation ongoing * Plan to initiate Phase | p
Slide 44: The VasoPET Opportunity
| The VasoPET Opportunity Est. 5" Year Revenue Millions ‘$408 million 08 o7 Est. PET Market Patients Market Size 0.6 Screening for 50 milion 300,000 95 atherosclerosis o4 Response to 3.8 million 380,000 0.3 therapy (statins) 02 Follow-up after 0.9 milion 90,000 0.1 heart attack ° Follow-up after 0.8
FluoroPharma Medical — Investor Presentation (March 2013) on 6ix